NCT04244656: Phase 1 -A Safety and Efficacy Study Evaluating CTX120 Relapsed Refractory Myeloma
NCT04398680: Phase 1: Belantamab Mafodotin With Normal & Impaired Hepatic Function (DREAMM 13) RRMM
IMPACT Study: The Immune Profiling with Antibody-based COVID-19 Testing - COVID-19 antibodies test
NCT04268199: Phase 2: Exploring Self-Administration of Chemo in the Home Environment (EASE)
NCT04246047: Phase 3: Belantamab Mafodotin, Bortezomib and Dex RRMM Myeloma (DREAMM 7)
MGUS (Monoclonal gammopathy of undetermined significance) - > Smoldering Myeloma -> Multiple Myeloma
The clonoSEQ® Watch Registry
CRI - Cancer Research Institute - Cancer Immunotherapy 101 with Dr. E. John Wherry
American Cancer Society: What is meant by Phase 1, Phase 2, Phase 3 Clinical Trials?
NCT04287855: Phase 2: Phase 2 Study of Isatuximab + Pomalidomide, Dex, Carfilzomib RRMM -IFM2018-03
NCT04504825: Phase 3: Efficacy & Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis
NCT04557098: Phase 2- Teclistamab, in Participants With Relapsed or Refractory Myeloma (MajesTEC-1)
FDA Approved for RRMM: Sarclisa (isatuximab-irfc) + Pomalyst (Pomalidomide) and Dexamethasone (IPd)
NCT04557150: Phase 1: Safety and Pharmacokinetics of Escalating Doses of RO7425781 RRMM Myeloma
Myeloma Canada: Patient Handbook - Managing Pain & Fatigue
UPTODATE: Patient education: Hematopoietic cell transplantation (bone marrow transplantation)
NCT04671251: Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma
NCT04564703: EMN26 Phase 2: Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM Patients
International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)
NCT04617925: Phase 2: EMN 27 - Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
NCT04541368: Phase 1: A Study of CS1-targeted CAR-T Cells Therapy for RRMM After BCMA CAR-T Thaerapy
NCT04398485: Phase 1: A Study of ION251 Administered to Patients With Relapsed/Refractory Myeloma
NCT04484623: Phase 3 - Belantamab Mafodotin & Pom/Dex (Pd) Vs Bortezomib & Pd in Ref. MM (DREAMM 8)
FDA Approved for RRMM: Belantamab mafodotin-blmf